Advances in Anti-IgE Therapy

Abstract EN

Omalizumab depletes free IgE in the blood and interstitial space and inhibits IgE binding to FcεRI on basophils, mast cells, and dendritic cells.

We stopped omalizumab treatment after four years.

Recurrences of urticaria symptoms were found to be higher in patients with chronic urticaria than recurrences of asthmatic symptoms in severe persistent asthma patients.

For the very first time, we used omalizumab in symptomatic therapy of recurrent laryngeal oedema and urticaria attacks in a patient with postoperative pulmonary carcinoid tumor for eight months.

During the four years of follow-up, no recurrence was noted in pulmonary carcinoid tumor.

Control PET CT results revealed normal findings.

After omalizumab treatment, laryngeal oedema and urticaria symptoms were decreased.

The most common adverse reaction from omalizumab is injection site induration, injection site itching, injection site pain, and bruising but the package insert contains warnings regarding parasitic infections.

While there are no reports of fatal anaphylaxis as a result of omalizumab, some cases have been serious and potentially life-threatening.

Therefore, the FDA requires that people receiving omalizumab be monitored in the physician’s office for a period of time after their injections.